Figure 1.

Deletion of RL-D6 or RL-T1 RANKL enhancers does not affect bone mass accrual. A, Schematic structure of the Tnfsf11 gene indicating the previously identified enhancer regions (D1–D7 and T1–T3), transcription factors (pCREB, STAT3/STAT5, and cFOS) and nuclear receptors (VDR/retinoid X receptor [RXR]) capable of binding to these enhancers, as well as signaling pathways stimulating these interactions (shown in parentheses). B–E, Body weights (B) and serial dual x-ray absorptiometry BMDs (C–E) of female D6KO (purple line) and T1KO (dark blue line) mice and their littermate controls (D6WT [pink line] and T1WT [light blue line]) were measured up to 24 weeks (W) of age. At each time point, the values represent the mean ± SD of 8 to 11 mice/group. *, P < .05 vs littermate WT group by t test. 1,25(OH)₂D₃), 1,25-dihydroxyvitamin D₃.